Full Text:   <2036>

Summary:  <1579>

CLC number: R589.2

On-line Access: 2015-05-04

Received: 2014-06-30

Revision Accepted: 2015-01-27

Crosschecked: 2015-04-09

Cited: 3

Clicked: 3250

Citations:  Bibtex RefMan EndNote GB/T7714

 ORCID:

Ming Zhong

http://orcid.org/0000-0003-0514-6028

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2015 Vol.16 No.5 P.380-387

http://doi.org/10.1631/jzus.B1400181


Pitavastatin calcium improves endothelial function and delays the progress of atherosclerosis in patients with hypercholesterolemia


Author(s):  Jing Zhao, Hui-min Yan, Ya Li, Jia Wang, Lu Han, Zhi-hao Wang, Meng-xiong Tang, Wei Zhang, Yun Zhang, Ming Zhong

Affiliation(s):  Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Qilu Hospital of Shandong University, Ji’nan 250012, China; more

Corresponding email(s):   zhongmingzm@gmail.com

Key Words:  Flow-mediated vasodilatation (FMD), Hypercholesterolemia (HC), Carotid intima-media thickness (IMT), Pitavastatin calcium


Jing Zhao, Hui-min Yan, Ya Li, Jia Wang, Lu Han, Zhi-hao Wang, Meng-xiong Tang, Wei Zhang, Yun Zhang, Ming Zhong. Pitavastatin calcium improves endothelial function and delays the progress of atherosclerosis in patients with hypercholesterolemia[J]. Journal of Zhejiang University Science B, 2015, 16(5): 380-387.

@article{title="Pitavastatin calcium improves endothelial function and delays the progress of atherosclerosis in patients with hypercholesterolemia",
author="Jing Zhao, Hui-min Yan, Ya Li, Jia Wang, Lu Han, Zhi-hao Wang, Meng-xiong Tang, Wei Zhang, Yun Zhang, Ming Zhong",
journal="Journal of Zhejiang University Science B",
volume="16",
number="5",
pages="380-387",
year="2015",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1400181"
}

%0 Journal Article
%T Pitavastatin calcium improves endothelial function and delays the progress of atherosclerosis in patients with hypercholesterolemia
%A Jing Zhao
%A Hui-min Yan
%A Ya Li
%A Jia Wang
%A Lu Han
%A Zhi-hao Wang
%A Meng-xiong Tang
%A Wei Zhang
%A Yun Zhang
%A Ming Zhong
%J Journal of Zhejiang University SCIENCE B
%V 16
%N 5
%P 380-387
%@ 1673-1581
%D 2015
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1400181

TY - JOUR
T1 - Pitavastatin calcium improves endothelial function and delays the progress of atherosclerosis in patients with hypercholesterolemia
A1 - Jing Zhao
A1 - Hui-min Yan
A1 - Ya Li
A1 - Jia Wang
A1 - Lu Han
A1 - Zhi-hao Wang
A1 - Meng-xiong Tang
A1 - Wei Zhang
A1 - Yun Zhang
A1 - Ming Zhong
J0 - Journal of Zhejiang University Science B
VL - 16
IS - 5
SP - 380
EP - 387
%@ 1673-1581
Y1 - 2015
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1400181


Abstract: 
Background: Statins have proven efficacy in inhibiting the onset and progress of atherosclerosis. The effectiveness of pitavastatin in reversing carotid atherosclerosis associated with hypercholesterolemia (HC) is unknown. Objectives: To explore the simultaneous effects of pitavastatin calcium on brachial arterial flow-mediated vasodilatation (FMD), carotid intima-media thickness (IMT), and arterial stiffness (β), three surrogate markers of atherosclerosis were studied in HC patients. Methods: A randomized, double-blind trial was performed with 40 HC subjects who fulfilled the inclusion/exclusion criteria. Patients were given pitavastatin calcium 1 mg/d (Group 1) or 2 mg/d (Group 2) for 8 weeks. There were 20 patients in each group, and 30 gender- and age-matched healthy subjects as controls were recruited. FMD of the brachial artery, carotid IMT, and arterial stiffness indicated by β were measured at baseline and at 8 weeks after starting pitavastatin calcium therapy using ultrasound techniques. Biochemical tests were also made on all subjects. Results: At baseline, higher total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C), reduced FMD, and increased β and IMT were observed in HC patients (P<0.001 for all) compared with controls. After 8 weeks, TC was decreased by 20.59%/27.56% and LDL-C 30.92%/35.64%, respectively, in comparison to baseline groups; the HC groups had reduced β and improved endothelial function over the 8-week follow-up (P<0.05–0.001); nonetheless, no significant alterations of IMT were found (P>0.05). Significant negative interactions between TC/LDL and FMD (P<0.05–0.001), positive interactions between TC and IMT (P=0.003) and between TC/LDL and β (P<0.001–0.000) were found. Conclusions: Treatment with pitavastatin calcium exerted favorable effects on endothelial function and arterial stiffness. It also improved carotid atherosclerosis in patients with HC.

匹伐他汀钙对高胆固醇血症患者动脉粥样硬化的影响

目的:观察匹伐他汀钙对高胆固醇血症患者外周血管的影响。
创新点:首次在国内发现匹伐他汀钙能够改善高胆固醇血症患者肱动脉和颈动脉血管内皮功能而且延缓其动脉粥样硬化发展,并首次证实改善内皮功能是匹伐他汀钙延缓其动脉粥样硬化发展的重要原因。
方法:按照入选排除标准,选取本院高胆固醇血症患者(HC),完成超声心动图检查的40例。根据剂量不同,分为两个剂量组:1mg剂量组20例(男性5例,女性15例,平均年龄(55.20±8.35)岁),2mg剂量组20例(男性9例,女性11例,平均年龄(57.56±6.09)岁)。访视结束后完成超声心动图检查的HC组36例,两个剂量组分别有2人失访。治疗后1mg剂量组18例(男性3例,女性15例,平均年龄(56.00±7.85)岁),2mg剂量组18例(男性7例,女性11例,平均年龄(57.79±6.46)岁)。选择本院同期体检中心30例正常人作为对照(年龄和性别均与病例组匹配,男性14例,女性16例,平均年龄(54.94±6.90)岁)。所有研究对象,均经隔夜禁食12~14小时,次日清晨抽取空腹肘静脉血,测定临床生化指标。采用Sequia512彩色多普勒超声诊断仪,应用高分辩率外周血管超声技术,检测HC治疗前后肱动脉血流介导性舒张功能(FMD)、颈动脉结构和功能。
结论:经匹伐他汀钙治疗8周后,高胆固醇血症患者血管功能明显改善,表现为FMD升高,僵硬度减小;颈动脉僵硬度和内中膜厚度(IMT)延缓进展与其内皮功能改善密切相关。

关键词:高胆固醇血症;内皮功能;颈动脉;匹伐他汀钙

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Anderson, T.J., 2006. Arterial stiffness or endothelial dysfunction as a surrogate marker of vascular risk. Can. J. Cardiol., 22(Suppl. B):72B-80B.

[2]Anderson, T.J., Uehata, A., Gerhard, M.D., et al., 1995. Close relation of endothelial function in the human coronary and peripheral circulations. J. Am. Coll. Cardiol., 26(5):1235-1241.

[3]Barter, P., Gotto, A.M., LaRosa, J.C., et al., 2007. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N. Engl. J. Med., 357(13):1301-1310.

[4]Bonetti, P.O., Lerman, L.O., Lerman, A., 2003. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb. Vasc. Biol., 23(2):168-175.

[5]Bots, M.L., Hoes, A.W., Koudstaal, P.J., et al., 1997. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation, 96(5):1432-1437.

[6]Burke, G.L., Evans, G.W., Riley, W.A., et al., 1995. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Stroke, 26(3):386-391.

[7]Chen, E.J., Adler, R.S., Carson, P.L., et al., 1995. Ultrasound tissue displacement imaging with application to breast cancer. Ultrasound Med. Biol., 21(9):1153-1162.

[8]Cho, S.H., Jeong, M.H., Park, I.H., et al., 2009. Endothelial dysfunction, increased carotid artery intima-media thickness and pulse wave velocity, and increased level of inflammatory markers are associated with variant angina. J. Cardiol., 54(2):183-191.

[9]Corretti, M.C., Anderson, T.J., Benjamin, E.J., et al., 2002. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J. Am. Coll. Cardiol., 39(2):257-265.

[10]de Groot, E., Jukema, J.W., Montauban van Swijndregt, A.D., et al., 1998. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J. Am. Coll. Cardiol., 31(7):1561-1567.

[11]Dembowski, E., Davidson, M.H., 2009. A review of lipid management in primary and secondary prevention. J. Cardiopulm. Rehabil. Prev., 29(1):2-12.

[12]Diehm, C., Kareem, S., Lawall, H., 2004. Epidemiology of peripheral arterial disease. Vasa, 33(4):183-189.

[13]Galle, J., Bassenge, E., Busse, R., 1990. Oxidised low density lipoproteins potentiate vasoconstrictions to various agonists by direct interaction with vascular smooth muscle. Circ. Res., 66(5):1287-1293.

[14]Hiro, T., Kimura, T., Morimoto, T., et al., 2009. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS Study). J. Am. Coll. Cardiol., 54(4):293-302.

[15]Juonala, M., Viikari, J.S., Laitinen, T., et al., 2004. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the Cardiovascular Risk in Young Finns Study. Circulation, 110(18):2918-2923.

[16]Leone, N., Ducimetière, P., Gariépy, J., et al., 2008. Distension of the carotid artery and risk of coronary events: the three-city study. Arterioscler. Thromb. Vasc. Biol., 28(7):1392-1397.

[17]Lorenz, M.W., Markus, H.S., Bots, M.L., et al., 2007. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation, 115(4):459-467.

[18]Lusis, A.J., 2000. Atherosclerosis. Nature, 407(6801):233-241.

[19]Makita, S., Ohira, A., Tachieda, R., et al., 2000. Dilation and reduced distensibility of carotid artery in patients with abdominal aortic aneurysms. Am. Heart J., 140(2):297-302.

[20]Neunteufl, T., Katzenschlager, R., Hassan, A., et al., 1997. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis, 129(1):111-118.

[21]Oliver, J.J., Webb, D.J., 2003. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. Arterioscler. Thromb. Vasc. Biol., 23(4):554-566.

[22]Petnehazy, T., Stokes, K.Y., Russell, J.M., et al., 2005. Angiotensin II type-1 receptor antagonism attenuates the inflammatory and thrombogenic responses to hypercholesterolemia in venules. Hypertension, 45(2):209-215.

[23]Raitakari, O.T., Juonala, M., Kähönen, M., et al., 2003. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA, 290(17):2277-2283.

[24]Ross, R., 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature, 362(6423):801-809.

[25]Ross, R., 1999. Atherosclerosis—an inflammatory disease. N. Engl. J. Med., 340(2):115-126.

[26]Serruys, P.W., de Feyter, P., Macaya, C., et al., 2002. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA, 287(24):3215-3222.

[27]Smilde, T.J., van Wissen, S., Wollersheim, H., et al., 2001. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet, 357(9256):577-581.

[28]Takase, B., Uehata, A., Akima, T., et al., 1998. Endothelium-dependent flow-mediated vasodilatation in coronary and brachial arteries in suspected coronary disease. Am. J. Cardiol., 82(12):1535-1539.

[29]Weidner, G., 2000. Why do men get more heart disease than women? An international perspective. J. Am. Coll. Health., 48(6):291-294.

[30]Yan, H.M., Zhao, J., Ma, D.Z., et al., 2011. The effect of pitavastatin calcium on endothelial dysfunction induced by hypercholesterolemia. Expert Opin. Pharmacother., 12(10):1463-1471.

[31]Yeboah, J., Crouse, J.R., Hsu, F.C., et al., 2007. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: the Cardiovascular Health Study. Circulation, 115(18):2390-2397.

[32]Yu, X.Y., Zhao, Y., Song, X.X., et al., 2014. Association between non-alcoholic fatty liver disease and arterial stiffness in the non-obese, non-hypertensive, and non-diabetic young and middle-aged Chinese population. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 15(10):879-887.

[33]Zanchetti, A., Bond, M.G., et al., Hennig, M., 2002. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European lacidipine study on atherosclerosis (ELISA), a randomized, double-blind, long-term trial. Circulation, 106(19):2422-2427.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2022 Journal of Zhejiang University-SCIENCE